| Trial ID: | L2344 |
| Source ID: | NCT00094757
|
| Associated Drug: |
Comparator: Sitagliptin 100 Mg
|
| Title: |
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00094757/results
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Comparator: sitagliptin 100 mg|DRUG: Comparator: sitagliptin 200 mg|DRUG: Comparator: placebo|DRUG: Comparator: pioglitazone
|
| Outcome Measures: |
Primary: Change From Baseline in A1C at Week 18, Hemoglobin A1C (A1C) is measured as percent. Thus this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent., Weeks 0-18 | Secondary: Change From Baseline in FPG at Week 18, The change from baseline reflects the Week 18 Fasting Plasma Glucose (FPG) minus the Week 0 FPG., Weeks 0-18|Change From Baseline in A1C at Week 54, A1C is measured as percent. Thus this change from baseline reflects the Week 54 A1C percent minus the Week 0 A1C percent., Weeks 0-54|Change From Baseline in FPG at Week 54, The change from baseline reflects the Week 54 FPG minus the Week 0 FPG., Weeks 0-54
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
521
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2004-10-06
|
| Completion Date: |
2006-04-28
|
| Results First Posted: |
2010-07-21
|
| Last Update Posted: |
2019-05-30
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00094757
|
